The Phase 2 clinical trial (HPV2-2303) sponsored by Centre Oscar Lambret aims to evaluate the efficacy of secondary HPV vaccination in women over 45 years who are chronic HPV carriers and have undergone treatment for high-grade cervical lesions. Given the increasing incidence of HPV-related cancers and the potential for Gardasil 9 to enhance HPV clearance, this study addresses a significant unmet medical need in an aging population. The trial's dual-cohort design allows for a comparative analysis of vaccinated versus non-vaccinated patients, which could provide valuable insights into the vaccine's effectiveness and safety profile. If successful, the findings may bolster Gardasil 9's market position and expand its indications, potentially leading to increased adoption in clinical practice. The study is currently recruiting, with an estimated enrollment of 85 patients, and is expected to complete by the end of 2031, positioning it well within the timeline for potential market impact.